Skip to content
value.today

Nephros, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2024 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, 23.5% a year (statements).

%

US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt or cash not on file: 0 to start with.

What today's price assumes

A market value of $36 M means free cash flow growing 48.6% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.

Revenue grew 23.5% a year over the last three years.

Cash-flow value of the shares
$6 M
-82% against the market value
Value of the whole business
$6 M
before net debt
Value from after year 10
69%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →18.48%20.98%23.48%25.98%28.48%
7.92%-82%-78%-73%-68%-61%
8.92%-85%-82%-78%-74%-69%
9.92%-87%-85%-82%-78%-74%
10.92%-89%-87%-85%-82%-78%
11.92%-91%-89%-87%-84%-81%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Medical Instruments: $29 M to $73 M, median $50 MPrice to salesPrice to sales of Medical Instruments: $37 M to $125 M, median $65 MPrice to bookPrice to book of Medical Instruments: $20 M to $67 M, median $45 MCash-flow value$0 M$34 M$67 M$101 M$135 MMarket value $36 M

Your own DCF model

A full discounted-cash-flow model of Nephros, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Medical Instruments

Multiples of its companies with a market value at most 60 days old, times Nephros, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Nephros, Inc.Applied toValue (25th to 75th)Companies
P/E24.5× / 42.4× / 61.3×18.7×net income $1 M$29 M to $73 M15
Price to sales2.0× / 3.5× / 6.6×1.6×revenue $19 M$37 M to $125 M23
Price to book2.0× / 4.4× / 6.6×3.5×book equity $10 M$20 M to $67 M23

Against its own history

Nephros, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

20.5×

Now below its median of 39.0×, in the bottom quarter of its range; range 20.5× to 286.2× over 19 months.

0×72×143×215×286×2026P/E 21×Median 39×

Price to sales

1.7×

Now below its median of 2.3×; range 1.1× to 13.5× over 29 months.

0×3×7×10×14×2020202120222023202420252026Price to sales 2×Median 2×

Price to book

3.5×

Now below its median of 4.4×; range 0.9× to 20.3× over 29 months.

0×5×10×15×20×2020202120222023202420252026Price to book 3×Median 4×

As of Oct 30, 2026

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$19 M$1 M$2 M———SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$14 M$0 M$-0 M$0 M$-1 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$14 M$-2 M$1 M$0 M$1 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$10 M$-7 M$-3 M$0 M$-3 M$-4 MSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$10 M$-4 M$-1 M$0 M$-1 M$-7 MSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$9 M$-5 M$-7 M$0 M$-7 M$-8 MSEC annual report (10-K, 20-F)